^
    Back
    Association details:
    Biomarker:CCR4 negative
    Cancer:Solid Tumor
    Drug:Poteligeo (mogamulizumab-kpkc) (CCR4 receptor antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.

    Excerpt:
    ...Patients with histologically confirmed, CCR4 negative lung, stomach, esophageal, ovarian or skin cancer....
    Trial ID:
    NCT01929486
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    PLoS One
    Title:

    Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors

    Published date:
    09/20/2023
    Excerpt:
    Forty-nine patients with CCR4-negative solid cancers were enrolled in the phase Ia and Ib trials on KW-0761...A partial response and stable disease were observed in 1 and 9 patients, respectively.
    DOI:
    10.1371/journal.pone.0291772